Vogenx is a clinical stage life science and drug development company focused on the development of novel therapeutics for the treatment of important diseases associated with dysfunctions in human metabolism including  post bariatric hypoglycemia (PBH), gastroparesis, and obesity.

Human metabolism is a complex process that involves many biochemicals, tissues, and organs throughout the body and refers to the ongoing biochemical processes that maintain the normal functioning of all living organisms.

The Company’s lead compound is a first-in-class, oral, small molecule drug candidate that inhibits postprandial glucose absorption and reduces secretion of insulin and gastric inhibitory peptide (GIP).